Clinical Trials Logo
  1. Home
  2. Contrast-induced Nephropathy
  3. NCT01061320

Efficacy of Alpha Tocopherol for Prevention of Contrast-induced Nephropathy in Chronic Kidney Disease (CKD) Patients

Contrast Induced Nephropathy Clinical Trial

Official title:
Efficacy of Alpha Tocopherol and New Biomarker (Urine NGAL) for Prevention and Early Diagnosis of Contrast-induced Nephropathy in CKD Patients Undergoing Elective Coronary Procedures

Clinical Trial Summary

The purpose of this study is to demonstrate the efficacy of alpha tocopherol for prevention contrast-induced nephropathy in CKD patients undergoing elective coronary procedures.

Clinical Trial Description

Contrast-induced nephropathy (CIN) increases the likelihood of patient morbidity and mortality following coronary procedures. Contrast agents cause an acute deterioration in renal function via the generation of reactive oxygen species. Vitamin E (alpha tocopherol)was demonstrated to be anti-oxidant and anti-inflammation. The present study was designed to evaluate the administration of antioxidant vitamin E (alpha tocopherol) as a means of preventing CIN in these patients. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01061320
Study type Interventional
Source Thammasat University
Contact
Status Enrolling by invitation
Phase Phase 3
Start date January 2010
Completion date December 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Completed NCT00634491 - Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy Phase 2
Terminated NCT00476619 - Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial Phase 4
Recruiting NCT03121053 - Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement Phase 4
Completed NCT02650336 - Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial N/A
Completed NCT01741896 - Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography? N/A
Terminated NCT00575419 - Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure Phase 1
Not yet recruiting NCT00392405 - Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate Phase 2
Completed NCT00292487 - Patients With Renal Impairment Undergoing CT Phase 4
Recruiting NCT04982419 - Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial Phase 2/Phase 3
Completed NCT00770614 - Hydration and Contrast-Induced Nephropathy in Primary Angioplasty Phase 4
Completed NCT01999517 - Contrast Nephropathy and Nitrates Phase 4
Recruiting NCT00702728 - Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention Phase 3
Completed NCT00531765 - Sodium Bicarbonate in Preventing Contrast Induced Nephropathy N/A
Completed NCT00639912 - Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction. Phase 4
Terminated NCT00494637 - The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy N/A
Completed NCT02516072 - Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy N/A
Active, not recruiting NCT01402232 - REduction of rIsk for Contrast Induced Nephropathy
Recruiting NCT02113540 - Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography Phase 3
Active, not recruiting NCT01456013 - Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients Phase 3